- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06427213
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
A Study of the Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, multicenter, investigator-initiated clinical trial to evaluate the efficacy and safety of zanubrutinib-containing regimens in the treatment of newly diagnosed elderly or young patients with high risk MCL, aiming to find a more optimal treatment regimen for elderly or young patients with high risk MCL to improve the efficacy, survival time and quality of life of patients.
In elderly patients arm:patients start with the induction therapy of zanubrutinib combined with obinutuzumab for 1 year and then entered the maintenance therapy of zanubrutinib orally until intolerable toxicity or disease progression
In young patients with high risk arm:patiens <65 years,and meet one or more of the following risk factors: TP53 mutation, blastoid/pleomorphic type, high sMIPI score. patients start with 6 cycles of induction therapy with zanubrutinib combined with R-BAC regimen, and the patients who achieve CR/PR and meet the transplantation criteria will receive ASCT consolidationand, then received maintenance therapy with zanubrutinib. otherwise, Patients who is ineligible for transplantation,will take zanubrutinib orally until intolerable toxicity or disease progression.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: keshu Zhou
- Phone Number: 0371-65587306
- Email: drzhouks77@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntary participation in clinical study; Fully understand and understand the study and sign the informed consent form (ICF);Willingness to follow and ability to complete all study steps
- Histopathologically confirmed mantle cell lymphoma according to the 5th edition of the World Health Organization (WHO),previous untreatment for mantle-cell lymphoma (MCL)
- The elderly group ≥65 years old;The young group was ≥18 years old and < 65 years old.
- ECOG Performance Status 0-3
- Life expectancy of at least 3 months
- At least one evaluable lesion according to 2014 Lugano criteria;
- Proper functioning of the major organs, no major heart, lung, liver, kidney, or immunodeficiency (no blood transfusion, granulocyte colony-stimulating factor, or other medical support within 7 days before starting the study) :Hemoglobin (HB)≥60 g/L;Absolute neutrophil count(ANC)≥0.5×10^9/L;Platelet count(PLT)≥50×10^9/L;AST and ALT ≤ 2.5 x ULN;Total bilirubin ≤ 1.5 times the ULN;Ccr≥40ml/min(Cockcroft-Gault );Left Ventricular Ejection Fraction (LVEF) ≥ 50%
Exclusion Criteria:
- The presence of other tumors could affect the study medication or interfere with the results;
- Patients require treatment with strong or moderate CYP3A inhibitors;
- Pregnant or lactating women;
- Known to be allergic to the test drug ingredients;
- Subjects of childbearing potential who are unwilling to use highly effective contraceptive methods;
- Live vaccination was administered within 28 days prior to treatment
- Known human immunodeficiency virus (HIV) infection or suggested active B or C infection The following serologic status of hepatitis C virus infection: 1) Hepatitis B virus (HBV) DNA positive. Positive hepatitis B surface antigen (HBsAg) or anti-hepatitis B core antibody (HBcAb) seropositive if HBV DNA is undetectable and willing to accept Monthly surveillance for HBV reactivation was eligible. 2) Hepatitis C virus (HCV) antibody positive. For patients with HCV antibodies present, if undetectable HCV RNA, can be included;
- Severe coagulopathy and serious impairment of heart, brain, lung, liver, kidney and other organs
- History of deep vein thrombosis (DVT) or pulmonary embolism (PE) within the past 12 months;
- Any risk that is considered by the investigator to be likely to affect the safety of the subjects or to pose a risk to the study And vital diseases, medical conditions, or organ system insufficiency.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Elder Patients(≥65)
Induction: Zanubrutinib and Obinutuzumab 1year Maintenance: Zanubrutinib continued until progression |
Zanubrutinib, 160mg PO BID. C1D17 continuously for 1 year or until progressive disease; Obinutuzumab :Obinutuzumab will be administered 1,000 mg intravenously on days 1, 8, and 15 of cycle 1, then 1,000 mg on day 1 of cycles 2 to 6, then 1,000 mg every 8 weeks,up to 20 doses. 1 cycle = 28 days. Maintenance: Zanubrutinib, 160mg PO BID |
Experimental: Young Patients with High risk (≥18,<65)
Induction: Zanubrutinib and R-BAC 6 cycles Consolidation: ASCT(If eligible for transplantation),Otherwise, the patient was directly entered into maintenance treatment Maintenance: Zanubrutinib continued until progression |
Induction: Zanubrutinib and R-BAC 6 cycles Consolidation: ASCT(If eligible for transplantation),Otherwise, the patient was directly entered into maintenance treatment Maintenance: Zanubrutinib continued until progression |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response rate after induction
Time Frame: 3 yeas
|
Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.
|
3 yeas
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Adverse Events
Time Frame: 5 years
|
Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0
|
5 years
|
Complete remission rate after Interim treatment
Time Frame: 3 years
|
Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria.
|
3 years
|
MRD negativity rate after induction
Time Frame: 3 years
|
MRD negativity rate after induction treatment
|
3 years
|
Progression free survival (PFS)
Time Frame: 5 years
|
The time from start of treatment to progression or death from any cause
|
5 years
|
Overall survival (OS)
Time Frame: 5 years
|
The time from start of treatment to death from any cause
|
5 years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Lymphoma, Mantle-Cell
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Tyrosine Kinase Inhibitors
- Obinutuzumab
- Zanubrutinib
Other Study ID Numbers
- IIT-TN MCL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Non-Hodgkin
-
Marker Therapeutics, Inc.RecruitingHodgkin Lymphoma | Non Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, Relapsed | Hodgkin's Lymphoma, Relapsed, AdultUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Mayo ClinicRecruitingIndolent B-Cell Non-Hodgkin Lymphoma | Recurrent Indolent Non-Hodgkin Lymphoma | Refractory Indolent Non-Hodgkin Lymphoma | Recurrent Indolent B-Cell Non-Hodgkin Lymphoma | Refractory Indolent B-Cell Non-Hodgkin LymphomaUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Stanford UniversityNational Institutes of Health (NIH); AmgenCompletedLymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Peripheral T-Cell | Lymphomas: Non-Hodgkin Cutaneous Lymphoma | Lymphomas: Non-Hodgkin Diffuse Large B-Cell | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell | Lymphomas: Non-Hodgkin Mantle Cell | Lymphomas: Non-Hodgkin Marginal... and other conditionsUnited States
Clinical Trials on Zanubrutinib,Obinutuzumab
-
Weill Medical College of Cornell UniversityGenentech, Inc.; BeiGeneRecruitingLeukemia, Lymphocytic, Chronic, B-CellUnited States
-
BeiGeneRecruitingMature B-Cell MalignanciesUnited States, Italy, Australia, New Zealand, Spain, United Kingdom, Germany
-
BeiGeneCompletedB-cell Lymphoid MalignanciesAustralia, Korea, Republic of, United States
-
iOMEDICO AGBeiGene Switzerland GmbHRecruitingFollicular Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Waldenström's MacroglobulinemiaGermany, Austria
-
Memorial Sloan Kettering Cancer CenterMassachusetts General Hospital; BeiGene USA, Inc.; Roche-GenentechRecruitingChronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)United States
-
Zhang Lei, MDRecruitingThrombocytopenia | Antiphospholipid Syndrome | TreatmentChina
-
BeiGeneRecruitingCLLUnited States, Spain, Australia, New Zealand, Korea, Republic of, China, Brazil, Netherlands, United Kingdom, Canada, Poland, Puerto Rico
-
BeiGeneActive, not recruitingRelapsed/Refractory Follicular Non-Hodgkin LymphomaKorea, Republic of, New Zealand, United States, China, Taiwan, Spain, Italy, Australia, Canada, United Kingdom, Belarus, Bulgaria, Czechia, France, Germany, Poland, Russian Federation
-
Fudan UniversityRecruiting
-
Institute of Hematology & Blood Diseases Hospital...RecruitingImmune Thrombocytopenia | TreatmentChina